Sfoglia per RIVISTA
ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
Collezione AO Cuneo

  

Items : 12

International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2022 Jan;33(1):57-66. doi: 10.1016/j.annonc.2021.09.017. Epub 2021 Oct 5.

2022
AO Cuneo
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Scagliotti GV; Manegold C; Monica V; Porcu L; Wiest G; Irtelli L; Dickgreber NJ; Caffo O; Pedrazzoli P; Bearz A; Griesinger F; Follador A; Folprecht G; Schmid-Bindert G; Reck M; Chiari R; Gregorc V; Santo A; Morabito A; Schena M; Valmadre G; Borra G; Kropf-Sanchen C; Ceribelli A; Stoelben E; Cauchi C; Colantonio I; Geissler M; Meyer A; et alii...

2022
AO Cuneo
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Porcu L; Manegold C; Scagliotti GV; Monica V; Wiest G; Irtelli L; Bearz A; Caffo O; Dickgreber NJ; Follador A; Pedrazzoli P; Griesinger F; Folprecht G; Reck M; Schmid-Bindert G; Santo A; Gregorc V; Chiari R; Morabito A; Borra G; Schena M; Kropf-Sanchen C; Valmadre G; Ceribelli A; Colantonio I; Cauchi C; Stoelben E; Ladage D; Geissler M; et alii...

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2019 Mar 1;30(3):418-423. doi: 10.1093/annonc/mdz007.

2019
AO Cuneo

Miglietta F; Orvieto E; Sanders M; Maiorana A; Piacentini F; Ferro A; Sarti S; Cagossi K; Bertone E; Garrone O; Rimanti A; Giotta F; Cavanna L; Musolino A; Frassoldati A; Brandes AA; Bisagni G; Conte P; Dieci MV; Balduzzi S; D'Amico R; Guarneri V;

Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2019 Dec 1;30(12):1969-1977. doi: 10.1093/annonc/mdz403.

2019
AO Cuneo

Marmorino F; Rossini D; Lonardi S; Moretto R; Zucchelli G; Aprile G; Dell'Aquila E; Ratti M; Bergamo F; Masi G; Urbano F; Ronzoni M; Libertini M; Borelli B; Randon G; Buonadonna A; Allegrini G; Pella N; Ricci V; Boccaccino A; Latiano TP; Cordio S; Passardi A; Tamburini E; Boni L; Falcone A; Cremolini C; Marmorino F; Rossini D; et alii...

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Jul;29(7):1528-1534. doi: 10.1093/annonc/mdy140. Epub 2018 Apr 20.

2018
AO Cuneo
AOU Città della Salute di Torino

Falcone A; Fontanini G; Boni L; Sensi E; Zagonel V; Masi G; Allegrini G; Granetto C; Buonadonna A; Marmorino F; Tonini G; Zaniboni A; Loupakis F; Ronzoni M; Racca P; Moretto R; Cortesi E; Tomasello G; Lonardi S; Bergamo F; Antoniotti C; Cremolini C; Cremolini C; Antoniotti C; Lonardi S; Bergamo F; Cortesi E; Tomasello G; Moretto R; et alii...

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Dec 1;29(12):2328-2333. doi: 10.1093/annonc/mdy414.

2018
AO Cuneo
AOU Città della Salute di Torino

Vicini R; Amaducci L; Bajardi EA; Beano A; Schirone A; Lombardo L; Moretti G; Giovanardi F; Pronzato P; Russo A; Cagossi K; Rimanti A; Zamagni C; Danese S; Maltoni R; Ferro A; Musolino A; Molino A; Gebbia V; Aieta M; Giotta F; Cavanna L; Piacentini F; Garrone O; Donadio M; Brandes AA; Bisagni G; Frassoldati A; Conte P; et alii...

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2017 Oct 1;28(10):2526-2532. doi: 10.1093/annonc/mdx344.

2017
AO Cuneo

Cohen EEW; Licitra LF; Burtness B; Fayette J; Gauler T; Clement PM; Grau JJ; Del Campo JM; Mailliez A; Haddad RI; Vermorken JB; Tahara M; Guigay J; Geoffrois L; Merlano MC; Dupuis N; Krämer N; Cong XJ; Gibson N; Solca F; Ehrnrooth E; Machiels JH;

The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2017 Dec 1;28(12):3051-3057. doi: 10.1093/annonc/mdx524.

2017
AO Cuneo

Zaucha JM; Malkowski B; Chauvie S; Subocz E; Tajer J; Kulikowski W; Fijolek-Warszewska A; Biggi A; Fallanca F; Kobylecka M; Dziuk M; Woszczyk D; Rybka J; Kroll-Balcerzak R; Bergesio F; Romanowicz A; Chamier-Cieminska A; Kurczab P; Giza A; Lesniewski-Kmak K; Zaucha R; Swietlik D; Wróbel T; Knopinska-Posluszny W; Walewski J; Gallamini A;

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2016 May;27(5):843-9. doi: 10.1093/annonc/mdw052. Epub 2016 Feb 9.

2016
AO Cuneo
AOU Città della Salute di Torino

Bustreo S; Ronzoni M; Buonadonna A; Bergamo F; Tomasello G; Tonini G; Allegrini G; Vitello S; Rossini D; Moretto R; Chiara S; Mancini ML; Granetto C; Lonardi S; Masi G; Loupakis F; Cremolini C; Barbara C; Boni L; Falcone A;

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2015 Jun;26(6):1188-1194. doi: 10.1093/annonc/mdv112. Epub 2015 Feb 23.

2015
AO Cuneo
AOU Città della Salute di Torino

Di Donato S; Granetto C; Bonetti A; D'Amico M; Vitello S; Longarini R; Barone C; Tonini G; Spadi R; Zaniboni A; Tomasello G; Cortesi E; Salvatore L; Masi G; Lonardi S; Antoniotti C; Cremolini C; Loupakis F; Boni L; Falcone A;

Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2015 Jun;26(6):1248-1253. doi: 10.1093/annonc/mdv132. Epub 2015 Mar 5.

2015
AO Cuneo

Roila F; Ruggeri B; Ballatori E; Fatigoni S; Caserta C; Licitra L; Mirabile A; Ionta MT; Massidda B; Cavanna L; Palladino MA; Tocci A; Fava S; Colantonio I; Angelelli L; Ciuffreda L; Fasola G; Zerilli F;

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2015 Apr;26(4):724-730. doi: 10.1093/annonc/mdv012. Epub 2015 Jan 18.

2015
AO Cuneo

Masi G; Salvatore L; Boni L; Loupakis F; Cremolini C; Fornaro L; Schirripa M; Cupini S; Barbara C; Safina V; Granetto C; Fea E; Antonuzzo L; Boni C; Allegrini G; Chiara S; Amoroso D; Bonetti A; Falcone A;